IsoRay, Inc. (ISR) saw its loss widen to $1.45 million, or $0.03 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $1.31 million, or $0.02 a share.

Revenue during the quarter dropped 13.54 percent to $1.03 million from $1.19 million in the previous year period. Gross margin for the quarter stood at negative 0.10 percent as compared to a positive 2.27 percent for the previous year period.

Operating loss for the quarter was $1.48 million, compared with an operating loss of $1.41 million in the previous year period.

"While not yet reflected in our financial results, our newly adopted, focused marketing approach that positions IsoRay and Cesium-131 as a leader in brachytherapy for prostate cancer treatment is gaining traction, supported by our recently expanded and experienced sales force. We are continuing to bolster the sales force, and replaced two salespeople in the second quarter. Our sales force now numbers six, which includes four salespeople that are new to IsoRay. We're also continuing to add content, case studies and other resources to our recently re-branded website, collateral marketing materials and a recently launched expanded social media presence, all in our effort to raise awareness of IsoRay and the advantages of Cesium-131. The sales force has become increasingly effective in delivering IsoRay's renewed message of commitment to prostate brachytherapy, which has been reinforced during follow-up visits and conversations with senior management, including myself," said Thomas LaVoy, chairman and chief executive officer.